Here is our list of the 11 best cancer stocks to buy right now.

Bristol Myers leans on new launches to offset legacy drug declines, while GSK's diverse portfolio and strong HIV lineup keep growth on track.

The Cleveland Clinic's Nathan Pennell, M.D., Ph.D., is switching to the Big Pharma realm to head up hematology and oncology ...

Bristol-Myers Squibb has been navigating some choppy waters but seems poised for a turnaround. Recently, shares have ticked ...

Bristol Myers Squibb appointed Nathan Pennell, MD, PhD, FASCO, as SVP, worldwide head of medical affairs for hematology and oncology, effective August 18. Nucleus RadioPharma hired former Food and ...

Bristol-Myers Squibb Company is pushing the boundaries with its latest clinical study on Deucravacitinib. The drug targets moderate to severe systemic lupus erythematosus (SLE). Employing a ...

The average dividend yield in the S&P 500 Index remains low at around 1.3%. As a result, many stocks have lower dividend ...

Pfizer Canada ULC and BioNTech SE (Nasdaq: BNTX) "BioNTech" announced today that Health Canada has authorized the LP.8.1 ...

Personalized and targeted cancer therapies are showing unprecedented promise, with novel approaches potentially ...